SIDP Antimicrobial Stewardship Certificate Program Antimicrobial Stewardship and Microbiology: Focus on Rapid Diagnostic Tests
|
|
- Pamela West
- 6 years ago
- Views:
Transcription
1 Antimicrobial Stewardship Certificate Program Antimicrobial Stewardship and Microbiology: Focus on Rapid Diagnostic Tests Karri A. Bauer, PharmD, BCPS (AQ-ID) Specialty Practice Pharmacist Infectious Diseases The Ohio State University Wexner Medical Center 1 Objectives Discuss the various rapid diagnostic technologies Evaluate the use of rapid diagnostic technologies on patient outcomes Determine considerations during the preimplementation, implementation, and postimplementation phases of rapid diagnostic technologies 2 1
2 Patient Case 62 year old male presented to the ED with cc of night sweats HPI: 3 day history of generalized fatigue, fevers and night sweats and nausea PMH: HTN, HLD, DM2 Physician Exam: Vitals: Temp F, HR 110, BP 120/70, RR 20, 98% on RA Blood cultures obtained prior to initiation of vancomycin + piperacillin/tazobactam 3 General Principles Basic Microbiology Direct examination Culture/Gram stain Rapid biochemical tests Antibody and antigen detection Average time to deliver antimicrobial susceptibility testing results to a physician is 40 hours Numerous studies have demonstrated the impact of inappropriate antimicrobial therapy on mortality Kerremans JJ, Verboom P, Stijnen T, et al. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J. Antimicrob Chemother 2008;61:
3 Dilemma with Conventional Methods Day 0 Day 1 Day 2 Day 3 Day 4 Positive Blood Culture Conventional Species ID Blood Draw Gram Stain Conventional Dx Empiric Rx Broad-spectrum Rx Targeted Rx Gram stain provides limited information. Cannot tell the species Culture is too slow Clinicians can t wait an additional 1-3 days to treat the infection Leads to inappropriate and ineffective therapy for some patients and unnecessarily therapy for others Introduction New advances in RDTs provide collaborative opportunities for antimicrobial stewardship programs (ASPs) Enhance functions of clinical microbiology laboratories Provide accurate organism identification Timely antimicrobial susceptibility testing data RDTs benefit the individual patient but also p increase the effectiveness of ASPs 3
4 Conventional/New Timeline Day 0 Day 1 Day 2 Day 3 Day 4 Positive Blood Culture Conventional Species ID Blood Draw Gram Stain Conventional Dx Empiric Rx Broad-spectrum Rx Targeted Rx Blood Draw Empiric Rx Positive Blood Culture Gram Stain Species ID Targeted Rx Rapid and accurate results on day 1 Supports decisions for appropriate and targeted therapy 1-3 days earlier than conventional methods Rapid Diagnostic Technologies 4
5 Polymerase Chain Reaction (PCR) Fluorescently labeled probe with primers Amplify target DNA Combines amplification and detection ti into 1 process Roche Molecular System s LightCycler SeptiFast MecA BD GeneOhm s Cdiff assay Cepheid s C. difficile assay Multiplex PCR Fluorescently labeled prove with > 1 set of primers Simultaneous detection of multiple organisms and resistant makers BD GeneOhm s Staph SR assay Cepheid s Xpert MRSA/SA blood culture and C. difficile/epi assays BioFire Diagnostics FilmArray 5
6 Nanoparticle Probe Nucleic acid extraction and PCR amplification Hybridization of target DNA to capture oligonucleotides on a microarray Signal amplification of hybridized probes provides an automated analysis Nanosphere s Verigene blood culture Grampositive and Gram-negative Verigene Gram Positive Blood Culture (BC-GP) Test Available Test Panels Species Staphylococcus aureus Staphylococcus epidermidis Staphylococcus lugdunensis Streptococcus anginosus Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pyogenes Enterococcus faecalis Genus Staphylococcus spp. Streptococcus spp. Micrococcus spp. Listeria spp. Resistance meca vana vanb Enterococcus faecium 6
7 Verigene Gram Negative Blood Culture (BC-GN) Test Available Test Panels Species Genus Escherichia coli Acinetobacter spp. Klebsiella pneumoniae Citrobacter spp. Klebsiella oxytoca Enterobacter spp. Pseudomonas aeruginosa Proteus spp. Resistance CTX-M KPC NDM VIM IMP OXA FilmArray Blood Culture Identification Panel Available Test Panels Gram-Positive Enterococcus Listeria monocytogenes Staphylococcus aureus Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pyogenes Streptococcus pyogenes Enterococcus faecalis Enterococcus faecium Gram-Negative Acinetobacter baumannii Haemophilus influenzae Neisseria meningitidis Pseudomonas aeruginosa Enterobacter cloacae Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Proteus spp. Serratia marcescens 7
8 Peptide Nucleic Acid Fluorescent In Situ Hybridization (PNA FISH) Synthetic oligonucleotide fluorescence-labeled probes Neutral charge of the synthetic molecule allows rapid hybridization to species-specific ribosomal RNA Fluorescence is detected using a fluorescence microscope QuickFISH (AdvanDx) Requires less setup time Faster turnaround time 90 minutes-20 minutes from positive blood cultures PNA FISH S. aureus Coagulase-negative staph Negative 8
9 Matrix-Assisted Laser Desorption- Ionization Time-of Flight Mass Spectrometry (MALDI-TOF) Mass spectrometry results in ionization and disintegration of a target molecule Mass/charge ratio of the resulting fragments is analyzed to produce a molecular signature Provides a profile or fingerprint of the organism Analyze thousands of samples/day from a variety of sources R id Di ti T h l i d Rapid Diagnostic Technologies and Antimicrobial Stewardship 9
10 Staphylococcus aureus S. aureus infections constitute a tremendous burden S. aureus bacteremia requires prompt microbiological diagnosis and antibiotic administration Vancomycin is often used empirically Use of antistaphylococcal -lactams have demonstrated superior clinical outcomes compared to vancomycin for MSSA infections Available RDTs Organism Detection time, h Technology Manufacturer Batching CLIA Designation Trade Name SA, CoNS 0.3 PNA QuickFISH AdvanDx No High S.aureus/CoN SPNA QuickFISH MRSA Immunochromatography Alere No Moderate Alere PBP2a Scarborough, Inc. Culture Colony Test S. aureus 0.2 Immunochromatography Alere Scarborough, Inc. MSSA, MRSA No Not rated BinaxNOW S. aureus Chromogenic medium BD No High BBL CHROMagar MRSA II MRSA 2 PCR Roche Diagnostics Yes High LightCycler MRSA g Staph SR MSSA, 2 Multiplex PCR BD GeneOhm Yes High BD GeneOhm MRSA, CoNS MSSA, MRSA, CoNS S. aureus, S. epidermidis 1 Multiplex PCR Cepheid No Moderate Xpert MRSA/SA BC 1 Multiplex Nanosphere No Moderate Verigene BC-GP MALDI-TOF MS and FilmArray can also be used. 10
11 meca Gene Testing and Intervention Carver PL, Lin S-W, DePestel DD, et al. Impact of meca gene testing and intervention by infectious diseases clinical pharmacists on time to optimal antimicrobial therapy for Staphylococcus aureus bacteremia at a university hospital. Clin Micro 2008;46: J Drug Therapy for Patients with MSSA Bacteremia Parta M, Goebel M, Thomas J, et al. Impact of an assay that enables rapid determination of Staphylococcus species and their drug susceptibility on the treatment of patients with positive blood culture results. Infect Control Hosp Epidemiol 2010;31(10):
12 Time to Antibiotic Switch Days p=0.02 p= Preintervention Postintervention MSSA MRSA Bauer KA, West JE, Balada-Llasat JM, et al. An antimicrobial stewardship program s impact with rapid polymerase chain reaction methicillin Staphylococcus aureus/s. aureus blood culture in patients with S. aureus bacteremia. Clin Infect Dis 2010;51(9): RDT and Stewardship Intervention- Hospital Costs 80,000 70, $69,737 60,000 50,000 40,000 30,000 20,000 10,000 0 Preintervention p=0.02 $48,350 Postintervention Bauer KA, West JE, Balada-Llasat JM, et al. An antimicrobial stewardship program s impact with rapid polymerase chain reaction methicillin Staphylococcus aureus/s. aureus blood culture in patients with S. aureus bacteremia. Clin Infect Dis 2010;51(9):
13 Coagulase-Negative Staphylococci spp. Often considered a contaminant Multiple positive blood cultures require therapy Clinicians often determine the positive blood cultures to represent contamination ASP PharmD Interventions for CoNS Using Rapid PCR Discontinuation of antistaphyloccal antibiotics, hours Total antibiotic exposure, days Infection-related LOS, days Preintervention Postinterventio n Infection-related costs $28,973 $20, Initiated vancomycin 7 (21%) P Wong JR, Bauer KA, Mangino JE, Goff DA. Antimicrobial stewardship pharmacist interventions for coagulasenegative staphylococci positive blood cultures using rapid polymerase chain reaction. Ann Pharmacother 2012; 46(11):
14 Assessment of PNA FISH CoNS in the Absence of Stewardship Intervention Holtzman C, Whitney D, Barlam T, et al. Assessment of impact of peptide nucleic acid fluorescence in situ hybridization of rapid identification of coagulase-negative staphylococci in the absence of antimicrobial stewardship intervention. J Clin Micro 2011;49(4): Enterococci spp. 3 rd most commonly isolated healthcareassociated organism Intrinsically resistant to many antibiotics May acquire additional resistant determinants VRE bacteremia associated with suboptimal patient outcomes Empiric therapy includes vancomycin, p py y, daptomycin, or linezolid 14
15 Available RDTs Organism Detectio Technology Manufactur Batchin CLSI Trade n time, h er g Designation Name E. faecalis, E. faecium E. faecalis, E. faecium (also detects VRE) 0.5 PNA QuickFISH AdvanDx No High Enterococcu s faecalis/oe PNA QuickFISH 2.5 Multiplex PCR Nanosphere No Moderate Verigene BC- GP MALDI-TOF MS and FilmArray can also be used. PNA FISH for Enterococcal Bactermia % p= % p< Time to therapy (days) 30-day mortality (%) Preintervention Postintervention Forrest GN, Roghmann MC, Toombs LS, et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 2008;52:
16 Gram-Negative Organisms Top healthcare priority Suboptimal patient outcomes Increased LOS, mortality, and healthcare costs Increased number are multidrug-resistant Limited treatment options Available RDTs Organism E. coli, K. pneumoniae, K. oxytoca, P. aeruginosa, S. marcescens, Acinetobacter spp., Proteus spp., Citrobacter spp., Enterobacter spp. E. coli, P. aeruginosa, K. pneumoniae Detectio n time, h Technology Manufactur er Batchin g CLSI Designation Trade Name 2.5 Multiplex PCR Nanosphere No Moderate Verigene BC- GN 0.5 PNA QuickFISH AdvanDx No High GNR Traffic Light PNA QuickFISHs E. coli, K. 1 Multiplex PCR BioFire Yes Moderate FilmArray pneumoniae, K. oxytoca, P. aeruginosa, A. baumannii, Enterobacter spp., Proteus spp, S. marcescens, H influenzae, N. meningitidis Diagnostics MALDI-TOF MS can also be used. System and Panels 16
17 PNA FISH Distinguishes P. aeruginosa from E. coli or K. pneumoniae after the recognition of Gramnegative bacilli of positive blood cultures Provides a key opportunity for stewardship programs to deescalate therapy Combination therapy Antipseudomonal therapy Integrating Rapid Pathogen Identification and ASP Length of Stay and Cost Outcomes in Survivors Outcome Preintervention cohort Intervention cohort P Hospital LOS 11.9 ± ± Hospital LOS after BSI onset 9.9 ± ± ICU LOS 7.3 ± ± ICU LOS after BSI onset Total hospital costs 6.1 ± ± $45,709 ± $61,806 $26,162 ± $28, Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 2013;137(9):
18 Impact of Rapid Organism Identification Using MALDI-TOF % of Patients Day All-Cause Mortality % p= % Days Length of Stay p= Preintervention Intervention 0 Preintervention Intervention Huang AM, Newton D, Kunapuli A. et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 2013;57(9): Impact of MALDI-TOF and ASP Intervention in Patients with A. baumannii Infections Hours p=<0.01 p=< Time to effective therapy Time to effective therapy > 0 Preintervention Intervention Wenzler E, Goff DA, Mangino JE, Reed EE, Wehr A, Bauer KA. Impact of rapid identification of Acinetobacter baumannii via matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) and antimicrobial stewardship intervention in patient with pneumonia and/or bacteremia. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Barcelona, Spain May
19 Candida spp. 4 th most most common cause of nosocomial bloodstream infections Time to positive blood culture and species identification can take several days Increase in the amount of time to effective antifungal therapy and hospital mortality RDTs for Candida spp. Rapid diagnostic T2Candida assay Candida species detected C. albicans, C. parapsilosis, C. krusei, C. glabrata, C. tropicalis MALDI-TOF All MS PNA-FISH C. albicans, C. parapsilosis, C. glabrata, C. krusei, C. tropicalis Date test is performed Day of blood culture Day of yeast identification Day of yeast identification Sensitivity Specificit y Positive predictive value 98% 98% 91% 94% 100% 94% 98% 98% 99% 19
20 T2 Candida Assay Magnetic resonance (MR) PCR Hybridization of DNA Probe-decorated nanoparticles Nanosphere microclusters Large changes in sample s T2MR signal Identifies 5 species of Candida Directly from whole blood Limits of detection-1 CFU/mL Rapid results 3 hours 98% positive agreement and 100% negative agreement Impact of PNA FISH on Mortality and Hospital Costs Clinical and Economic Outcomes Outcome No PNA FISH PNA FISH P Time to appropriate <0.001 therapy, days All cause mortality 26.8% 7.7% 0.14 ICU mortality 41.7% 5.9% 0.02 Cost avoidance > $2.2 million/year Gamage DC, Olson DP, Stickell LH. Significant decreases in mortality and hospital costs after laboratory testing with PNA FISH. In: 51 st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September
21 Community Hospital Experienced with PNA FISH Length of stay (LOS) costs Daily LOS cost per patient LOS cost savings/patient t Patients with LOS Reduction C. glabrata All yeast $2,607 $33, $2,607 $15, Total LOS cost savings $372,801 $328,482 C. albicans/c. glabrata $7,790 $7,790 PNA FISH Costs Net benefit to hospital per patient $34,261 $15,769 Net benefit to hospital per day $2,635 $2,628 Annual net benefit e to hospital $196,633 $172,774 Length of time between yeast detection in blood culture and identification to the species level was decreased significantly (p=0.001) For patients with candidemia caused by C. glabrata, LOS decreased significantly (p=0.008) and significant difference in time to appropriate antifungal therapy (p=0.03) Rush T, Verma P. Do rapid results with the C. albicans/c. glabrata PNA FISH assay have an impact on patient management? A community hospital experience. In: 111 th Annual ASM Meeting, New Orleans, LA May 2011:2563. Candidemia-Time to Positivity 162 patients with candidemia 58 ± 17 years Average time to yeast identification 2.22 ± 13days 1.3 Average time to start antifungal therapy 3.5 ± 2.1 days Candida Species Time to Positivity Days (mean ± SD) C. albicans 1.7 ± 1.0 C. glabrata 2.6 ± 1.5 C. tropicals 1.4 ± 1.1 C. parapsilosis 2.2 ± 0.89 Aitken SL, Beyda ND, Shah DN, et al. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in the era of rapid diagnostics. Annals of Pharmacotherapy 2014;48(6):
22 Time to Antifungal Initiation- Comparison of RDTs erapy Days to initiation of th ± ± ±1.3 T2Candida MALDI TOF MS PNA FISH Rapid Diagnostic Test Use of T2Candida on the day of the blood culture resulted in 3136 to 6078 fewer doses of echinocandins annually per 5000 patients Aitken SL, Beyda ND, Shah DN, et al. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in the era of rapid diagnostics. Annals of Pharmacotherapy 2014;48(6): Clostridium difficile Increasingly challenging infection Increases in severity of disease, clinical failure, and recurrences Epidemiology has changed NAP1/BI/027 22
23 Available RDTs Detection time, h Technolog y Manufacturer Batching Automate d CLSI Designation Trade Name 1 LAMP Meridian Yes Yes Moderate Illumigene Bioscience C. difficile 2 PCR BD GeneOhm Yes Yes Not rated BD GeneOhm Cdiff Assay 0.5 Multiplex PCR 0 5 utpe PCR Cepheid No Yes Moderate Xpert C. difficile 0.75 Multiplex Cepheid e No Yes Moderate Xpert 3 PCR Gen-Probe Prodesse C. difficile/ep i Yes Yes Not rated ProGastro Cd Assay Important Considerations PCR technology is more sensitive Rate of positive tests can more than double Important t to educate medical staff and hospital administration Implement strict criteria for testing > 3 unformed watery stools in a 24-hour period Formed stool rejected unless lab notified of ileus Samples should not be sent as test of cure 23
24 Preimplementation DO YOUR HOMEWORK-BEST DATA IS YOUR OWN DATA Organisms Prevalence Problematic Reportable Timing of results Real-time Batch Sensitivity/specificity Purchase/lease Physical space Complexity Resources for clinical and economic outcomes Implementation Education Timing Real time Batch Communication of results Pharmacist/physician resources Pharmacist/physician role Intervention documentation/acceptance rate 24
25 Postimplementation Workflow Education Documentation/Justification Time to effective/optimal therapy Time to discontinuation or de-escalation Time to ID consult Repeat blood cultures 30-day readmission Length of stay Hospital cost of infection Hospital cost Conclusions Collaboration between microbiology and stewardship will continue to grow Innovative technology Game of speed Microbiologist and stewardship justification Clinically and economically 25
THE FAST AND THE SUSCEPTIBLE: RAPID DIAGNOSTICS IN INFECTIOUS DISEASE
THE FAST AND THE SUSCEPTIBLE: RAPID DIAGNOSTICS IN INFECTIOUS DISEASE Brandon Dionne, PharmD, BCPS, AAHIVP Assistant Clinical Professor Northeastern University Clinical Pharmacy Faculty Infectious Diseases
More informationReview of Rapid Diagnostic Tests Used by Antimicrobial Stewardship Programs
SUPPLEMENT ARTICLE Review of Rapid Diagnostic Tests Used by Antimicrobial Stewardship Programs Karri A. Bauer, 1 Katherine K. Perez, 2,3,4 Graeme N. Forrest, 5 and Debra A. Goff 1 1 Department of Pharmacy,
More informationRAPID IDENTIFICATION OF RESISTANCE MECHANISMS
RAPID IDENTIFICATION OF RESISTANCE MECHANISMS Christine C. Ginocchio, PhD, MT (ASCP) Professor of Medicine, Hofstra North Shore-LIJ School of Medicine, NY VP, Global Microbiology Affairs, biomerieux VP,
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationRapid Rewards. Identification from Positive Blood Cultures
Rapid Rewards Identification from Positive Blood Cultures Carol Young, MT(ASCP) University of Michigan Health System Clinical Microbiology Laboratory youngc@umich.edu Disclosures Carol Young BioRad (chromogenic
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationThe Role and Effect of Antimicrobial Stewardship Programs Within the Hospital and How Rapid Diagnostics Can Make an Impact
The Role and Effect of Antimicrobial Stewardship Programs Within the Hospital and How Rapid Diagnostics Can Make an Impact The Harvard community has made this article openly available. Please share how
More informationAntimicrobial de-escalation in the ICU
Antimicrobial de-escalation in the ICU A FOCUS ON EVIDENCE-BASED STRATEGIES Dave Leedahl, PharmD, BCPS-AQ ID, BCCCP Pharmacy Clinical Manager Sanford Health Fargo, ND, USA I have no conflicts of interest
More informationANTIBIOTICS IN THE ER:
ANTIBIOTICS IN THE ER: EXPLORING THE ROLE OF ANTIMICROBIAL STEWARDSHIP IN THE EMERGENCY DEPARTMENT ANGELINA DAVIS, PHARMD, MS, BCPS (AQ-ID) LIAISON CLINICAL PHARMACIST DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationRecommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data
Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory
More informationCME/SAM. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting
Microbiology and Infectious Disease / Xpert MRSA/SA in Pediatric Blood Cultures Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting David H. Spencer, MD, PhD,
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More information10/19/2017. Objectives
2 Northeast Florida Society of Health System Pharmacists Fall Meeting 2017 Microbiology's ole in Antimicrobial Stewardship-A Microbiologist's Perspective Yvette S. McCarter, PhD, D(ABMM) Director, Clinical
More informationOverview of Antimicrobial Stewardship
Overview of Antimicrobial Stewardship Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Colleges of Medicine and Public Health Medical Director, Antimicrobial Stewardship Program The Ohio
More information4/4/2017. Update on Diagnostic Assays for Rapid Detection of Bacteremia. Disclosures. Learning Objectives
Update on Diagnostic Assays for Rapid Detection of Bacteremia Karen C Carroll, M.D. Professor of Pathology Director, Division of Medical Microbiology The Johns Hopkins University School of Medicine 1 Disclosures
More informationDrive More Efficient Clinical Action by Streamlining the Interpretation of Test Results
White Paper: Templated Report Comments Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results Background The availability of rapid, multiplexed technologies for the comprehensive
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More information3/10/2016. Faster Microbiology An Outcome Analysis. Disclaimer. Short Topic Objectives
Faster Microbiology An Outcome Analysis James E. Lee, Ph.D. Disclaimer The views expressed are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationNUOVE IPOTESI e MODELLI di STEWARDSHIP
Esperienze di successo di antimicrobial stewardship Bologna, 18 novembre 2014 NUOVE IPOTESI e MODELLI di STEWARDSHIP Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Interventions
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationMAJOR ARTICLE. MALDI-TOF; antimicrobial stewardship; bacteremia; candidemia.
MAJOR ARTICLE Impact of Rapid Organism Identification via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Combined With Antimicrobial Stewardship Team Intervention in Adult Patients With Bacteremia
More informationPreserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical
More informationStudy Type of PCR Primers Identified microorganisms
Study Type of PCR Primers Identified microorganisms Portillo et al, Marín et al, Jacovides et al, Real-time multiplex PCR (SeptiFasta, Roche Diagnostics) 16S rr gene was amplified using conventional PCR.
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationWENDY WILLIAMS, MT(AMT) MSAH DIRECTOR LABORATORY AND PATHOLOGY SERVICES. Appalachian Regional Healthcare System apprhs.org
Incorporating Automation and Rapid Diagnostic Technologies into the Micro Lab's Lean Workflow to Boost Productivity, Shorten Length of Stay, and Improve Antibiotic Utilization WENDY WILLIAMS, MT(AMT) MSAH
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationFinnzymes Oy. PathoProof Mastitis PCR Assay. Real time PCR based mastitis testing in milk monitoring programs
PathoProof TM Mastitis PCR Assay Mikko Koskinen, Ph.D. Director, Diagnostics, Finnzymes Oy Real time PCR based mastitis testing in milk monitoring programs PathoProof Mastitis PCR Assay Comparison of the
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationCan we trust the Xpert?
Can we trust the Xpert? An evaluation of the Xpert MRSA/SA BC System and an assessment of potential clinical impact Dr Kessendri Reddy Division of Medical Microbiology, NHLS Tygerberg Fakulteit Geneeskunde
More informationInfection Linelist. Infections Occurred Between 10/1/ :00:00 AM To 11/1/ :00:00 AM 2RCW2. Gastroenteritis (Adult) Urinary Tract
Infection Linelist Infections Occurred Between 10/1/2013 12:00:00 AM To 11/1/2013 12:00:00 AM 2RCW2 10/9/13 02407693 36890294 2094 1 32 M CLOSTRIDIUM DIFFICILE 10/26/13 99342791 37024716 2046 1 42 M CLOSTRIDIUM
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationHPN HOSPITALIZED PNEUMONIA APPLICATION
HPN HOSPITALIZED PNEUMONIA APPLICATION Investigational Use. Not available for Sale in the United States. Content UNYVERO HPN HOSPITALIZED PNEUMONIA APPLICATION The Unyvero HPN Pneumonia Application combines
More informationThe Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED
JCM Accepts, published online ahead of print on 7 May 2008 J. Clin. Microbiol. doi:10.1128/jcm.00801-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationConfron'ng An'microbial Resistance: Stewardship and Diagnos'cs
Confron'ng An'microbial Resistance: Stewardship and Diagnos'cs Stuart B. Levy, MD Dis2nguished Professor of Molecular Biology and Microbiology and of Medicine; Director, Center for Adapta2on Gene2cs and
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationSYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data
508 SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data Physical Properties Active Ingredient: Ethyl Alcohol 62% (70% v/v) Appearance: Clear, Colorless Solution Fragrance: Floral Form:
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationAntimicrobial Stewardship: efective implementation for improved clinical outcomes
The Challenge of MDR and XDR infections; Barcelona September 2018 Antimicrobial Stewardship: efective implementation for improved clinical outcomes José Miguel Cisneros Herreros Infectious Diseases Department
More informationUNDERSTANDING THE ANTIBIOGRAM
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationThe SUCCESS model for laboratory performance and execution of rapid molecular diagnostics in patients with sepsis
The SUCCESS model for laboratory performance and execution of rapid molecular diagnostics in patients with sepsis Mhair Dekmezian, MD, Stacy G. Beal, MD, Mary Jane Damashek, MT (ASCP) SM, Raul Benavides,
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationSolution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim
Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Program/Project Description, including Goals What was the problem to be solved? How was it identified? What baseline data existed?
More informationLiofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms
Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Microbiology Products since 1983 Liofilchem Chromatic ESBL Selective
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationRisk of organism acquisition from prior room occupants: A systematic review and meta analysis
Risk of organism acquisition from prior room occupants: A systematic review and meta analysis A/Professor Brett Mitchell 1-2 Dr Stephanie Dancer 3 Dr Malcolm Anderson 1 Emily Dehn 1 1 Avondale College;
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More information10/11/2017. Objectives. Case #1
Majdi Al-Hasan, MBBS Associate Professor of Medicine University of South Carolina School of Medicine Objectives Examine antibiotic resistance rates in hospitals and community Demonstrate association between
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES
ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado
More informationAntibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE
Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationSuccess for a MRSA Reduction Program: Role of Surveillance and Testing
Success for a MRSA Reduction Program: Role of Surveillance and Testing Singapore July 13, 2009 Lance R. Peterson, MD Director of Microbiology and Infectious Disease Research Associate Epidemiologist, NorthShore
More informationValidation of the PathoProof TM Mastitis PCR Assay for Bacterial Identification from Milk Recording Samples
Validation of the PathoProof TM Mastitis PCR Assay for Bacterial Identification from Milk Recording Samples Mikko Koskinen, Ph.D. Finnzymes Oy Benefits of using DHI samples for mastitis testing Overview
More informationRapid diagnostics: an AMS tool? Serap Şimşek-Yavuz Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Rapid diagnostics: an AMS tool????? Serap Şimşek-Yavuz Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 1 Rapid diagnostics (RDT): an AMS tool? Outline Why we need rapid diagnostics
More informationASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies
ASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies Theresa Jaso, PharmD, BCPS (AQ-ID) Network Clinical Pharmacy Specialist Infectious Diseases Seton Healthcare Family Ascension
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationThe Cost of Antibiotic Resistance: What Every Healthcare Executive Should Know
The Cost of Antibiotic Resistance: What Every Healthcare Executive Should Know JCR National Infection Prevention and Control Conference 2009 Mastering Powerful and Practical Infection Prevention Strategies
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationThe Nuts and Bolts of Antibiograms in Long-Term Care Facilities
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationPreventing and Responding to Antibiotic Resistant Infections in New Hampshire
Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Benjamin P. Chan, MD, MPH NH Dept. of Health & Human Services Division of Public Health Services May 23, 2017 To bring a greater
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationBest Practices for Antimicrobial Stewardship Programs. October 25, :00 AM 5:00 PM New Orleans, LA Room:
Best Practices for Antimicrobial Stewardship Programs October 25, 2016 8:00 AM 5:00 PM New Orleans, LA Room: 288-290 Co-organized by The Society for Healthcare Epidemiology of America (SHEA) and Pediatric
More informationRapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management. Martin McHugh Clinical Scientist
Rapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management Martin McHugh Clinical Scientist 1 Staphylococcal Bacteraemia SAB is an important burden on
More informationNo-leaching. No-resistance. No-toxicity. >99.999% Introducing BIOGUARD. Best-in-class dressings for your infection control program
Introducing BIOGUARD No-leaching. >99.999% No-resistance. No-toxicity. Just cost-efficient, broad-spectrum, rapid effectiveness you can rely on. Best-in-class dressings for your infection control program
More informationHOSPITAL-ACQUIRED INFECTIONS AND QASM PATIENTS
Royal Australasian College of Surgeons Queensland Audit of Surgical Mortality (QASM) HOSPITAL-ACQUIRED INFECTIONS AND QASM PATIENTS (JULY 2011 TO JUNE 2016) Contact Queensland Audit of Surgical Mortality
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationMASTITIS DNA SCREENING
Trusted Dairy Laboratory Services for more than 75 years MASTITIS DNA SCREENING Short Reference Guide Eurofins DQCI 5205 Quincy Street, Mounds View, MN 55112 P: 763-785-0484 F: 763-785-0584 E: DQCIinfo@eurofinsUS.com
More information